Licensing · Latin America · Announced 24 Oct 2026
Orchid Pharma → Laboratorio Libra
Orchid Pharma licensed its antibiotic Exblifep to Uruguay's Laboratorio Libra for nine Latin American markets, an opportunity Orchid puts at about US$80 million over ten years, with Orchid supplying finished product.
Parties: Orchid Pharma (India) → Laboratorio Libra (Uruguay)
- Deal type
- Licensing
- Value
- $80m
- Territory
- Chile, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Panama, Paraguay, Uruguay
- Therapeutic area
- Infectious Disease
- Asset
- Exblifep (cefepime/enmetazobactam)
- Announced
- 24 Oct 2026
Our analysis
Why this matters
Orchid Pharma announced on 24 October 2026 a licensing and supply agreement with Laboratorio Libra for Exblifep (cefepime/enmetazobactam), a carbapenem-sparing antibiotic for complicated urinary tract infections and hospital- and ventilator-acquired pneumonia caused by Gram-negative pathogens. Libra gets exclusive rights to register, import and market the product in Chile, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Panama, Paraguay and Uruguay. Orchid will manufacture and supply the finished product.
Orchid describes the deal as a potential commercial opportunity of about US$80 million over the first 10 years, based on projected demand. Upfront and milestone terms were not disclosed. Launch in each market depends on national regulatory approval; Exblifep already holds FDA and EMA approvals.
The full analysis is free to read with a work email on this page.